Payment overview · 2025
General Payments
$77,334.86
196 reported records · 26 companies
Healthcare provider profile · identity verified
Jon C George, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Interventional Cardiology · PHILADELPHIA, PA · NPI 1992746721
Verified facts
What the public records show
CMS Open Payments records show Jon C George, MD received $77,334.86 in general payments during 2025 across 196 reported records.
Medtronic, Inc. accounted for 54.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 43 associated products.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Entresto by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$42,218.20 | 54.6% | 101 | 2025 |
| Siemens Medical Solutions USA, Inc. | Unresolved — no canonical attribution shown | $14,118.48 | 18.3% | 16 | 2025 |
| Penumbra, Inc. | Unresolved — no canonical attribution shown | $6,153.41 | 8.0% | 6 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $5,670.86 | 7.3% | 7 | 2025 |
| CORDIS US CORP. | Unresolved — no canonical attribution shown | $2,748.56 | 3.5% | 5 | 2025 |
| AngioDynamics, Inc. | Unresolved — no canonical attribution shown | $1,189.50 | 1.5% | 3 | 2025 |
| Recor Medical Inc | Unresolved — no canonical attribution shown | $1,012.12 | 1.3% | 7 | 2025 |
| Infraredx, Inc. | Unresolved — no canonical attribution shown | $1,000.00 | 1.3% | 1 | 2025 |
| Terumo Medical Corporation | Unresolved — no canonical attribution shown | $900.00 | 1.2% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $352.43 | 0.5% | 6 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $292.27 | 0.4% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $245.43 | 0.3% | 9 | 2025 |
| ASAHI INTECC USA, INC. | Unresolved — no canonical attribution shown | $226.48 | 0.3% | 3 | 2025 |
| Becton, Dickinson and Company | Unresolved — no canonical attribution shown | $200.99 | 0.3% | 2 | 2025 |
| Cagent Vascular INC | Unresolved — no canonical attribution shown | $177.86 | 0.2% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $169.26 | 0.2% | 6 | 2025 |
| Bard Peripheral Vascular, Inc. | Unresolved — no canonical attribution shown | $146.97 | 0.2% | 2 | 2025 |
| Reflow Medical Inc | Unresolved — no canonical attribution shown | $128.97 | 0.2% | 3 | 2025 |
| Shockwave Medical, Inc | Unresolved — no canonical attribution shown | $78.00 | 0.1% | 2 | 2025 |
| Endologix LLC | Unresolved — no canonical attribution shown | $77.75 | 0.1% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $58.76 | 0.1% | 3 | 2025 |
| Inquis Medical, Inc. | Unresolved — no canonical attribution shown | $56.43 | 0.1% | 1 | 2025 |
| Galderma Laboratories, L.P. | Unresolved — no canonical attribution shown | $38.46 | 0.1% | 2 | 2025 |
| Nipro Medical Corporation | Unresolved — no canonical attribution shown | $30.00 | 0.0% | 1 | 2025 |
| Teleflex LLC | Unresolved — no canonical attribution shown | $25.29 | 0.0% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $18.38 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $36,400.00 | 7 |
| Consulting Fee | $26,100.00 | 15 |
| Food and Beverage | $7,517.47 | 148 |
| Travel and Lodging | $6,359.05 | 25 |
| Long term medical supply or device loan | $958.34 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VENASEAL Normalized: venaseal |
Device | Medtronic, Inc. | $17,330.63 | 19 | 2025 |
Source payment records
|
|||||
| HAWKONE Normalized: hawkone |
Device | Medtronic, Inc. | $16,172.52 | 10 | 2025 |
Source payment records
|
|||||
| Indigo System Normalized: indigo system |
Device | Penumbra, Inc. | $6,153.41 | 6 | 2025 |
Source payment records
|
|||||
| IGT Devices Undivided Normalized: igt devices undivided |
Device | Philips North America LLC | $5,436.97 | 4 | 2025 |
Source payment records
|
|||||
| TURBOHAWK Normalized: turbohawk |
Device | Medtronic, Inc. | $4,234.90 | 38 | 2025 |
Source payment records
|
|||||
| MYNX CONTROL VENOUS Normalized: mynx control venous |
Device | CORDIS US CORP. | $2,549.69 | 3 | 2025 |
Source payment records
|
|||||
| AURYON LASER SYSTEM 100-120 VAC Normalized: auryon laser system 100 120 vac |
Device | AngioDynamics, Inc. | $1,189.50 | 3 | 2025 |
Source payment records
|
|||||
| Artis icono floor Normalized: artis icono floor |
Device | Siemens Medical Solutions USA, Inc. | $1,058.54 | 7 | 2025 |
Source payment records
|
|||||
| Paradise Ultrasound Renal Denervation System Normalized: paradise ultrasound renal denervation system |
Device | Recor Medical Inc | $1,012.12 | 7 | 2025 |
Source payment records
|
|||||
| NAVICROSS Normalized: navicross |
Device | Terumo Medical Corporation | $900.00 | 1 | 2025 |
Source payment records
|
|||||
| SYMPLICITY G3 Normalized: symplicity g3 |
Device | Medtronic, Inc. | $779.59 | 21 | 2025 |
Source payment records
|
|||||
| AVVIGO Guidance System Normalized: avvigo guidance system |
Device | Boston Scientific Corporation | $347.76 | 5 | 2025 |
Source payment records
|
|||||
| RotarexS 6 F x 135 cm Normalized: rotarexs 6 f x 135 cm |
Device | Bard Peripheral Vascular, Inc., Becton, Dickinson and Company | $316.01 | 3 | 2025 |
Source payment records
|
|||||
| CT THROMBECTOMY SYSTEM KIT Normalized: ct thrombectomy system kit |
Device | Stryker Corporation | $292.27 | 3 | 2025 |
Source payment records
|
|||||
| FLOWTRIEVER CATHETER, S Normalized: flowtriever catheter s |
Device | Stryker Corporation | $292.27 | 3 | 2025 |
Source payment records
|
|||||
| COREVALVE EVOLUT R Normalized: corevalve evolut r |
Device | Medtronic, Inc. | $283.96 | 3 | 2025 |
Source payment records
|
|||||
| Serrantor Normalized: serrantor |
Device | Cagent Vascular INC | $177.86 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $169.26 | 6 | 2025 |
Source payment records
|
|||||
| SELUTION SLR PTA Normalized: selution slr pta |
Device | CORDIS US CORP. | $168.39 | 1 | 2025 |
Source payment records
|
|||||
| Asahi Coronary Wires Normalized: asahi coronary wires |
Device | ASAHI INTECC USA, INC. | $141.59 | 1 | 2025 |
Source payment records
|
|||||
| OPTIS Normalized: optis |
Device | Abbott Laboratories | $124.98 | 1 | 2025 |
Source payment records
|
|||||
| INeb Devices Normalized: ineb devices |
Device | Philips North America LLC | $122.71 | 1 | 2025 |
Source payment records
|
|||||
| ABRE Normalized: abre |
Device | Medtronic, Inc. | $117.04 | 6 | 2025 |
Source payment records
|
|||||
| IV Other Normalized: iv other |
Device | Philips North America LLC | $96.22 | 1 | 2025 |
Source payment records
|
|||||
| Asahi Interventional Radiology Wires Normalized: asahi interventional radiology wires |
Device | ASAHI INTECC USA, INC. | $84.89 | 2 | 2025 |
Source payment records
|
|||||
| Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Normalized: shockwave ivl system with the shockwave c2 coronary ivl catheter |
Device | Shockwave Medical, Inc | $78.00 | 2 | 2025 |
Source payment records
|
|||||
| ENDOCROSS Device Normalized: endocross device |
Device | Endologix LLC | $77.75 | 1 | 2025 |
Source payment records
|
|||||
| Torus Stent Graft System Normalized: torus stent graft system |
Device | Endologix LLC | $77.75 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $58.76 | 3 | 2025 |
Source payment records
|
|||||
| Aventus Normalized: aventus |
Device | Inquis Medical, Inc. | $56.43 | 1 | 2025 |
Source payment records
|
|||||
| JOT DX Normalized: jot dx |
Device | Abbott Laboratories | $43.84 | 1 | 2025 |
Source payment records
|
|||||
| DYSPORT Normalized: dysport |
Drug | Galderma Laboratories, L.P. | $38.46 | 2 | 2025 |
Source payment records
|
|||||
| Fluency Endovascular Stent Graft Normalized: fluency endovascular stent graft |
Device | Bard Peripheral Vascular, Inc. | $31.95 | 1 | 2025 |
Source payment records
|
|||||
| RADIAL 360 Normalized: radial 360 |
Device | CORDIS US CORP. | $30.48 | 1 | 2025 |
Source payment records
|
|||||
| Makoto Normalized: makoto |
Device | Nipro Medical Corporation | $30.00 | 1 | 2025 |
Source payment records
|
|||||
| ESPRIT Normalized: esprit |
Device | Abbott Laboratories | $29.43 | 1 | 2025 |
Source payment records
|
|||||
| IN.PACT ADMIRAL Normalized: in pact admiral |
Device | Medtronic, Inc. | $28.34 | 1 | 2025 |
Source payment records
|
|||||
| DIAMONDBACK PERIPHERAL Normalized: diamondback peripheral |
Device | Abbott Laboratories | $27.04 | 1 | 2025 |
Source payment records
|
|||||
| TURNPIKE Normalized: turnpike |
Device | Teleflex LLC | $25.29 | 1 | 2025 |
Source payment records
|
|||||
| PRESSUREWIRE Normalized: pressurewire |
Device | Abbott Laboratories | $20.14 | 5 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $18.38 | 1 | 2025 |
Source payment records
|
|||||
| Peripheral Vascular Undivided Normalized: peripheral vascular undivided |
Device | Philips North America LLC | $14.96 | 1 | 2025 |
Source payment records
|
|||||
| General - Vascular Intervention Normalized: general vascular intervention |
Device | Boston Scientific Corporation | $4.67 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Clopidogrel | Clopidogrel Bisulfate | 157 | 49 |
| Metoprolol Succinate | Metoprolol Succinate | 114 | 38 |
| Atorvastatin Calcium | Atorvastatin Calcium | 109 | 34 |
| Losartan Potassium | Losartan Potassium | 88 | 28 |
| Amlodipine Besylate | Amlodipine Besylate | 73 | 23 |
| Carvedilol | Carvedilol | 60 | 20 |
| Eliquis | Apixaban | 59 | 16 |
| Lisinopril | Lisinopril | 58 | 19 |
| Furosemide | Furosemide | 51 | 13 |
| Entresto | Sacubitril/Valsartan | 44 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 37 | 19 |
| Cilostazol | Cilostazol | 25 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 24 | suppressed |
| Xarelto | Rivaroxaban | 22 | suppressed |
| Nitroglycerin | Nitroglycerin | 17 | 12 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 15 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 14 | suppressed |
| Simvastatin | Simvastatin | 14 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 13 | suppressed |
| Brilinta | Ticagrelor | 12 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 12 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $77,334.86 · 196 records | Medtronic, Inc. | ABRE, AURYON LASER SYSTEM 100-120 VAC, AVVIGO Guidance System, Artis icono floor, Asahi Coronary Wires, Asahi Interventional Radiology Wires, Aventus, COREVALVE EVOLUT R, CT THROMBECTOMY SYSTEM KIT, DIAMONDBACK PERIPHERAL, DYSPORT, ENDOCROSS Device, ESPRIT, FLOWTRIEVER CATHETER, S, Fluency Endovascular Stent Graft, General - Vascular Intervention, HAWKONE, IGT Devices Undivided, IN.PACT ADMIRAL, INeb Devices, IV Other, Indigo System, JARDIANCE, JOT DX, LEQVIO, MYNX CONTROL VENOUS, Makoto, NAVICROSS, OPTIS, PRESSUREWIRE, Paradise Ultrasound Renal Denervation System, Peripheral Vascular Undivided, RADIAL 360, REPATHA, RotarexS 6 F x 135 cm, SELUTION SLR PTA, SYMPLICITY G3, Serrantor, Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter, TURBOHAWK, TURNPIKE, Torus Stent Graft System, VENASEAL | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Novartis Pharmaceuticals Corporation?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error